Evidence map›Paper›PMID 41385030›Full record

ArticleMedical oncology (Northwood, London, England)2025

A new approach for elimination of apoptotic resistance caused by MDM2/MDMX amplification in chronic lymphocytic leukemia: combination of ALRN-6924 and radiofrequency exposure.

Berrak Kurt, Handan Kayhan, Elçin Özgür Büyükatalay, Görkem Kısmalı

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Berrak Kurt *General Directorate of Agricultural Research and Policies, Ankara, Türkiye.
Handan Kayhan *Department of Adult Hematology, Faculty of Medicine, Gazi University, Ankara, Türkiye. handankayhan@gazi.edu.tr.ORCID http://orcid.org/0000-0003-4967-2740
Elçin Özgür BüyükatalayDepartment of Biophysics, Faculty of Medicine, Gazi University, Ankara, Türkiye.
Görkem KısmalıDepartment of Biochemistry, Faculty of Veterinary Medicine, Ankara University, Ankara, Türkiye.

Funding

Türkiye Sağlık Enstitüleri Başkanlığı 21259
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by mature B lymphocyte accumulation and frequent MDM2/MDMX overexpression, leading to p53 inactivation and apoptotic resistance. ALRN-6924, a stapled peptide dual inhibitor, targets MDM2/MDMX to restore p53 function. This study evaluated ALRN-6924 efficacy alone and combined with radiofrequency (RF) exposure in CLL cell lines. Molecular docking assessed ALRN-6924-MDM2 binding affinity. Cytotoxic and apoptotic effects were evaluated using XTT assays and flow cytometry in HG-3 (wild-type p53) and MEC-1 (mutant p53) cell lines. Treatments included ALRN-6924 monotherapy and combination with 900 MHz RF exposure (120 mW/cm

Indexed as

ApoptosisLeukemia, Lymphocytic, Chronic, B-CellNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Cell Cycle ProteinsCell Line, TumorCombined Modality TherapyHumansMolecular Docking SimulationTumor Suppressor Protein p53Cell Cycle ProteinsMDM2 protein, humanMDM4 protein, humanNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53ALRN-6924ApoptosisChronic lymphocytic leukemiaMDM2MDMXp53 tumor suppressorRadiofrequency exposureTargeted therapy

Identifiers

PMID41385030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.